Tango's Vopimetostat Combo Hits 82% ORR in Pancreatic Cancer; Phase 3 Set for 1H 2027
TNGX has more than doubled off its 52-week low of $6.69 on elevated volume (2.0× avg).
Summary
Tango reported an 82% response rate and 88% nine-month PFS rate for vopimetostat plus daraxonrasib in pretreated pancreatic cancer, and laid out a 484-patient randomized Phase 3 in front-line disease for the first half of 2027. It also cut about 14% of staff and stopped novel target discovery to fund the PRMT5 programs.
Key Events · Product Development and Regulatory · TNGX
-
82% ORR in Pretreated Pancreatic Cancer
In 22 efficacy-evaluable 2L/3L MTAP-deleted, RAS-mutant PDAC patients, vopimetostat plus daraxonrasib produced an 82% ORR (18/22), median PFS not reached, an 88% 9-month PFS rate and 100% disease control.
-
Phase 3 Registrational Design Disclosed
Following FDA interactions, Tango plans a global, randomized 1:1 trial of vopimetostat 200 mg plus daraxonrasib 100 mg versus standard-of-care chemotherapy in front-line MTAP-deleted PDAC, N=484, dual primary endpoints ORR and PFS, initiation expected in 1H 2027.
-
14% Workforce Reduction Approved
The Board approved a strategic reprioritization on October 22, 2026 to focus on PRMT5 therapies, cutting approximately 14% of headcount mostly from research and deprioritizing novel target discovery.
-
Zoldonrasib Arm Shows 54% ORR
Vopimetostat plus zoldonrasib in MTAP-deleted, KRAS G12D PDAC produced a 54% ORR (19/35), a 61% 9-month PFS rate and 97% DCR, with no DLTs and no withdrawals due to treatment-related adverse events.
Analysis · TNGX · Life Sciences
The updated Phase 1/2 data confirm the June 2026 signal with longer follow-up: an 82% objective response rate (18 of 22), median PFS not yet reached and an 88% 9-month PFS rate in second/third-line MTAP-deleted, RAS-mutant pancreatic cancer, with no dose-limiting toxicities at the 200 mg dose level. More important for the thesis, FDA interactions have produced an agreed registrational path — a 484-patient, 1:1 randomized Phase 3 against chemotherapy in front-line disease, starting in the first half of 2027, with a second-line accelerated-approval discussion also planned. Against that, the Board approved a reprioritization on October 22 that cuts roughly 14% of the workforce, mostly research, and stops novel target discovery to concentrate spending on vopimetostat and TNG456. The company had $1.0B in cash as of June 30, 2026, so this is a focus decision rather than a funding emergency, but it narrows the pipeline to a single lead asset whose value now hinges on the Phase 3 executing on schedule.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNGX was trading at $31.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $6.69 to $34.39. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.